Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

264.21 +2.15 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
49 50 Next >
Amgen's Planning to Take a Bite Out of Cancer. Here's What It Means for the Stock.
Its new approach to treating cancer is more than just a nibble around the edges. 
Via The Motley Fool
Should You Buy the Dogs of the Dow in 2024?
The popular dividend-investing strategy has been around for years. Is it right for you? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
P/E Ratio Insights for Amgen
Via Benzinga
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
ABBV: This Top Biotech Just Went On A Buying Spree
AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
Via Talk Markets
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Why NASDAQ:AMGN is a Top Pick for Dividend Investors.
Balancing Dividends and Fundamentals: The Case of AMGEN INC (NASDAQ:AMGN). 
Via Chartmill
How Is The Market Feeling About Amgen?
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments. 
Via InvestorPlace
What's Going On Johnson & Johnson Stock Today?
JNJ reports strong earnings, beats expectations for Q4 of 2023, with increased sales and successful acquisitions. Stock closes lower, settles talc litigation, and delays competitor's launch. 
Via Benzinga
Topics Earnings
Exposures Financial
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually. 
Via The Motley Fool
5 Magnificent Dividend Growth Stocks to Buy and Hold Forever
These dividend growers ought to shine in 2024 and beyond. 
Via The Motley Fool
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups. 
Via Benzinga
Exposures Product Safety
Dividend Income Update December 2023
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. 
Via Talk Markets
Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
Via Benzinga
Topics ETFs
Stocks Struggle As U.S. Dollar Sees Safety Bid
Once again, we are seeing stocks struggle whenever the dollar catches a bid. But not all hope is lost for bulls, as various semiconductor stocks continue to hold up well. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run. 
Via The Motley Fool
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains
Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
Via Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END 
Via FinancialNewsMedia
3 health care stocks off to strong starts in 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
Cramer shared his insights during his attendance at JPMorgan's healthcare conference, 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END 
Via FinancialNewsMedia
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.